M. Diago
About
M. Diago is a scholar working on Hepatology, Epidemiology and Rheumatology.
According to data from OpenAlex, M. Diago has authored 131 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Hepatology, 83 papers in Epidemiology and 29 papers in Rheumatology. Recurrent topics in M. Diago's work include Hepatitis C virus research (106 papers), Liver Disease Diagnosis and Treatment (65 papers) and Hepatitis B Virus Studies (51 papers). M. Diago is often cited by papers focused on Hepatitis C virus research (106 papers), Liver Disease Diagnosis and Treatment (65 papers) and Hepatitis B Virus Studies (51 papers). M. Diago collaborates with scholars based in Spain, United States and Germany. M. Diago's co-authors include Mitchell L. Shiffman, Joseph H. Hoffman, K. Rajender Reddy, Michael Fried, Fernando Lopes Gonçales, Antonio Craxı̀, Daniel Dhumeaux, Coleman I. Smith, George Marinos and Dieter Häussinger and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and PLoS ONE.
In The Last Decade
M. Diago
127 papers receiving 12.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| M. Diago Spain | 34 | 10.8k | 10.7k | 1.2k | 990 | 976 | 131 | 12.8k | ||
| Yasuji Arase Japan | 52 | 8.7k 0.8× | 9.1k 0.8× | 1.1k 0.9× | 873 0.9× | 714 0.7× | 394 | 11.6k | ||
| Fumitaka Suzuki Japan | 54 | 9.1k 0.8× | 9.6k 0.9× | 551 0.5× | 1.1k 1.1× | 766 0.8× | 404 | 11.5k | ||
| Tetsuya Hosaka Japan | 47 | 7.3k 0.7× | 7.3k 0.7× | 755 0.6× | 667 0.7× | 531 0.5× | 324 | 9.0k | ||
| Wan‐Long Chuang Taiwan | 53 | 8.3k 0.8× | 8.5k 0.8× | 563 0.5× | 733 0.7× | 616 0.6× | 513 | 11.1k | ||
| Mario Rizzetto Italy | 55 | 10.8k 1.0× | 8.4k 0.8× | 1.7k 1.4× | 1.0k 1.0× | 395 0.4× | 308 | 13.0k | ||
| Tarik Asselah France | 58 | 9.3k 0.9× | 9.3k 0.9× | 428 0.4× | 1.3k 1.3× | 684 0.7× | 290 | 12.0k | ||
| Jenny Heathcote Canada | 53 | 9.9k 0.9× | 10.0k 0.9× | 645 0.6× | 843 0.9× | 954 1.0× | 175 | 12.6k | ||
| Eiji Tanaka Japan | 53 | 7.7k 0.7× | 7.9k 0.7× | 412 0.4× | 595 0.6× | 795 0.8× | 280 | 11.2k | ||
| P Opolon France | 41 | 9.2k 0.9× | 9.5k 0.9× | 690 0.6× | 926 0.9× | 1.0k 1.0× | 161 | 12.1k | ||
| Robert P. Perrillo United States | 44 | 8.9k 0.8× | 8.4k 0.8× | 413 0.4× | 1.0k 1.0× | 621 0.6× | 119 | 10.1k |
Countries citing papers authored by M. Diago
Since
Specialization
Citations
This map shows the geographic impact of M. Diago's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Diago with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Diago more than expected).
Fields of papers citing papers by M. Diago
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by M. Diago. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Diago. The network helps show where M. Diago may publish in the future.
Co-authorship network of co-authors of M. Diago
This figure shows the co-authorship network connecting the top 25 collaborators of M. Diago. A scholar is included among the top collaborators of M. Diago based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Diago. M. Diago is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cardona, Concepción Gimeno, et al.. (2025). Current prevalence of hepatitis delta diagnosis in Valencia, Spain. Scientific Reports. 15(1). 7584–7584.
2.
Berg, Thomas, Pietro Andreoné, Stanislas Pol, et al.. (2014). Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study. Liver International. 35(2). 448–454.
3.
Colombo, Massimo, Ola Weiland, Daniel E. Cohen, et al.. (2014). SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin. Hepatology. 60.
4.
Romero‐Gómez, Manuel, Ramón Planas, Javier Ampuero, et al.. (2013). Meta‐analysis: pegylated interferon α‐2a achieves higher early virological responses than α‐2b in chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 37(11). 1065–1073.
5.
Wedemeyer, Heiner, Yun‐Fan Liaw, Henry Lik-Yuen Chan, et al.. (2013). No association between IL28B genotype and response to peginterferon alfa-2a (40KD) in HBe antigen-positive and HBe antigen-negative patients with chronic hepatitis B in three large randomized clinical studies. Hepatology. 58.
6.
Romero‐Gómez, Manuel, Ramón Planas, R. Solà, et al.. (2012). 1154 PEGINTERFERON ALPHA-2A ACHIEVES HIGHER EARLY VIROLOGICAL RESPONSES (RVR AND CEVR) THAN PEGINTERFERON ALPHA-2B IN CHRONIC HEPATITIS C: META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (RCT). Journal of Hepatology. 56. S456–S456.
7.
Foster, Graham R., Stefan Zeuzem, Pietro Andreoné, et al.. (2011). 6 SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORIZATION. Journal of Hepatology. 54. S3–S4.
8.
Zeuzem, Stefan, Pietro Andreoné, Stanislas Pol, et al.. (2011). 5 REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN. Journal of Hepatology. 54. S3–S3.
9.
Foster, Graham R., Stefan Zeuzem, Pietro Andreoné, et al.. (2011). OP03 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results: Abstract OP03 Table 1. Gut. 60(Suppl 2). A50.3–A51.
10.
Ruiz‐Extremera, A., R. Quiles, Ana Belén Barragán Martín, et al.. (2011). Plasma Ribavirin Trough Concentrations During Treatment of Chronic Hepatitis C in Genotype-1 Patients. Journal of Clinical Gastroenterology. 46(4). 328–333.
11.
Díez, Crisanto, Helena Masnou, Ramón Planas, et al.. (2010). Prophylactic Treatment With Escitalopram of Pegylated Interferon Alfa-2a–Induced Depression in Hepatitis C. The Journal of Clinical Psychiatry. 72(4). 522–528.
12.
Romero‐Gómez, Manuel, M. Diago, Raúl J. Andrade, et al.. (2009). Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa‐2a plus ribavirin†‡. Hepatology. 50(6). 1702–1708.
13.
Diago, M.. (2007). ¿Mejora el tratamiento antiviral el curso clínico de la cirrosis por virus de la hepatitis C?. Gastroenterología y Hepatología. 30(2). 85–92.
14.
Salmerón, Javier, M. Diago, Raúl J. Andrade, et al.. (2006). Induction doses of interferon‐α‐2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non‐responders to interferon monotherapy: a randomized trial. Journal of Viral Hepatitis. 14(2). 89–95.
15.
Pappas, S. Chris, Lisa M. Nyberg, Susan Greenbloom, et al.. (2006). 734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial. Journal of Hepatology. 44. S271–S271.
16.
Jensen, Dorte Møller, Pietro Andreoné, Y. Benhamou, et al.. (2006). 583 Safety of peginterferon α-2a (40KD) (PEGASYS®) [PEG-IFNα-2a (40KD)] plus ribavirin (COPEGUS®) among pegylated interferon α-2b (12KD)/ribavirin non-responders: Interim analysis of the repeat study. Journal of Hepatology. 44. S216–S217.
17.
18.
Ferenci, Peter, Michael Fried, Mitchell L. Shiffman, et al.. (2005). Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. Journal of Hepatology. 43(3). 425–433.
19.
Romero‐Gómez, Manuel, I. Wichmann, Javier Crespo, et al.. (2004). Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis. The American Journal of Gastroenterology. 99(11). 2150–2157.
20.
Enríquez–Navascués, José M., Adolfo Gallego, Xavier Torras, et al.. (2000). Retreatment for 24 vs 48 weeks with interferon‐α2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. Journal of Viral Hepatitis. 7(6). 403–408.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Yasuji Arase Breakdown of academic impact, for papers by Fumitaka Suzuki Breakdown of academic impact, for papers by Tetsuya Hosaka Breakdown of academic impact, for papers by Wan‐Long Chuang Breakdown of academic impact, for papers by Mario Rizzetto Breakdown of academic impact, for papers by Tarik Asselah Breakdown of academic impact, for papers by Jenny Heathcote Breakdown of academic impact, for papers by Eiji Tanaka Breakdown of academic impact, for papers by P Opolon Breakdown of academic impact, for papers by Robert P. Perrillo